Drug Azilect Approved By FDA - Treatment For Early Stage and Late State
with Levodopa - Side Effects
May 17th 2006
The Food and Drug
Administration (FDA) approved a new drug by Israeli drug maker Teva
Pharmaceutical Industries in Tel Aviv for the treatment of Parkinson’s
disease. The molecular identity is called Azilect (rasagiline) and is a
monoamine oxidase type--B (MAO-B) inhibitor that blocks the breakdown of
dopamine. Dopamine is a chemical that sends information to the parts of
the brain that control movement and coordination.
The drug has been
approved for both early and late stages of the disease. Azilect was
approved for use as an initial single drug therapy in early Parkinson's
disease, and as an addition to levodopa for advanced stages. Levodopa
has been a standard treatment for Parkinson’s disease.
Dr. Steven Galson
said "This is a welcome development for the more than 50,000 Americans
who are each year diagnosed with Parkinson's disease. Parkinson's is a
relentless disease with limited treatment options, and each new therapy
is an important addition to the physicians' treatment options." Galson
is Director of the Center for Drug Evaluation and Research.